Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases

被引:15
作者
Albano, F
Specchia, G
Anelli, L
Zagaria, A
Storlazzi, CT
Buquicchio, C
Roberti, MG
Liso, V
Rocchi, M
机构
[1] Univ Bari, Sez Genet, DAPEG, I-70126 Bari, Italy
[2] Univ Bari, Dept Hematol, I-70126 Bari, Italy
[3] Univ Foggia, Dept Hematol, Foggia, Italy
关键词
D O I
10.1002/gcc.10183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Philadelphia (Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML) and is observed in more than 90% of CML cases. At diagnosis, in 5-10% of CML patients the Ph chromosome is derived from variant translocations other than the standard t(9;22). Deletions adjacent to the translocation junction on the derivative chromosome 9 were recently described by different groups. The deletions may identify a subgroup with a worse prognosis. The presence of similar deletions on the third derivative other than the 9 and 22 chromosomes in CML with variant translocation has never been investigated. We studied three cases of CML variants showing relatively large deletions on the third chromosome involved in the translocation. Known tumor-suppressor genes (TSGs) or genes involved in signal transduction and in the modulation of cell proliferation were found to be located inside these deleted regions. As an alternative to Knudson's two-hit model, the "haplo-insufficiency" hypothesis suggests that the deletion of a single allele of a TSG can play an important role in tumor progression. Our findings suggest that great attention should be paid to the molecular cytogenetic characterization of variant t(9;22) CML patients to unveil fully the biological heterogeneity of CML. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:353 / 360
页数:8
相关论文
共 33 条
[1]   Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect [J].
Chen, HW ;
Sandler, DP ;
Taylor, JA ;
Shore, DL ;
Liu, E ;
Bloomfield, CD ;
Bell, DA .
LANCET, 1996, 347 (8997) :295-297
[2]   CtBP, an unconventional transcriptional corepressor in development and oncogenesis [J].
Chinnadurai, G .
MOLECULAR CELL, 2002, 9 (02) :213-224
[3]   Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene:: expression profiling, resistance to interferon therapy, and poor prognosis [J].
Cohen, N ;
Rozenfeld-Granot, G ;
Hardan, I ;
Brok-Simoni, F ;
Amariglio, N ;
Rechavi, G ;
Trakhtenbrot, L .
CANCER GENETICS AND CYTOGENETICS, 2001, 128 (02) :114-119
[4]   Accommodating haploinsufficient tumour suppressor genes in Knudson's model [J].
Cook, WD ;
McCaw, BJ .
ONCOGENE, 2000, 19 (30) :3434-3438
[5]   COMPLEX CHROMOSOMAL TRANSLOCATIONS IN THE PHILADELPHIA-CHROMOSOME LEUKEMIAS - SERIAL TRANSLOCATIONS OR A CONCERTED GENOMIC REARRANGEMENT [J].
FITZGERALD, PH ;
MORRIS, CM .
CANCER GENETICS AND CYTOGENETICS, 1991, 57 (02) :143-151
[6]   Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1 [J].
Haase, D ;
Binder, C ;
Bünger, E ;
Fonatsch, C ;
Streubel, B ;
Schnittger, S ;
Griesinger, F ;
Westphal, G ;
Schoch, C ;
Knopp, A ;
Berkovicz, D ;
Krieger, O ;
Wörmann, B ;
Hilgers, R ;
Hallier, E ;
Schulz, T .
LEUKEMIA RESEARCH, 2002, 26 (03) :249-254
[7]   TRANSLOCATION OF C-ABL TO MASKED PH IN CHRONIC MYELOID-LEUKEMIA [J].
HAGEMEIJER, A ;
DEKLEIN, A ;
GODDESALZ, E ;
TURCCAREL, C ;
SMIT, EME ;
VANAGTHOVEN, AJ ;
GROSVELD, GC .
CANCER GENETICS AND CYTOGENETICS, 1985, 18 (02) :95-104
[8]   Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression [J].
Horne, MC ;
Goolsby, GL ;
Donaldson, KL ;
Tran, D ;
Neubauer, M ;
Wahls, AF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) :6050-6061
[9]   Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [J].
Huntly, BJP ;
Reid, AG ;
Bench, AJ ;
Campbell, LJ ;
Telford, N ;
Shepherd, P ;
Szer, J ;
Prince, HM ;
Turner, P ;
Grace, C ;
Nacheva, EP ;
Green, AR .
BLOOD, 2001, 98 (06) :1732-1738
[10]   Death and anti-death: Tumour resistance to apoptosis [J].
Igney, FH ;
Krammer, PH .
NATURE REVIEWS CANCER, 2002, 2 (04) :277-288